Guangdong Zhongrun Drug Research and Development

Guangdong Zhongrun Drug Research and Development is a pharmaceutical R&D enterprise headquartered in Guangzhou, China, specializing in the development of innovative small molecule drugs and high-end generics. The company focuses on therapeutic areas including metabolic disorders, cardiovascular diseases, and anti-infectives, with a strong emphasis on gout and hyperuricemia treatments. Its lead clinical candidate, ZR-01, is a potent xanthine oxidase inhibitor currently undergoing clinical evaluation for the management of chronic gout. In addition to its internal pipeline, the company provides contract research services, leveraging its expertise in medicinal chemistry and pharmacology to support drug discovery for domestic and international partners.